Bersacapavir

DB19035InvestigationalSmall molecule

Bersacapavir is under investigation in clinical trial NCT03365947 (Study of ARO-HBV in Normal Adult Volunteers and Patients With Hepatitis B Virus (HBV)).

Mechanism: Pharmacologically active on Capsid protein
Curator reviewed
Formula / weight: C₁₆H₁₄F₄N₄O₃S · 418.37 g/mol (avg)
Also known as: 1h-pyrrole-2-carboxamide, n-(3-cyano-4-fluorophenyl)-1-methyl-4-((((1s)-2,2,2-trifluoro-1-methylethyl)amino)sulfonyl)- · N-(3-cyano-4-fluorophenyl)-1-methyl-4-(((2s)-1,1,1-trifluoro-2-propanyl)sulfamoyl)-1hpyrrole-2-carboxamide
Code names: JNJ-56136379 · JNJ-6379

Resolves to

Compound

UNII2456KW2166CAS1638266-40-6ChEMBLCHEMBL4744254

Structure

InChIKeySBVBIDUKSBJYEF-VIFPVBQESA-NSMILESC[C@H](NS(=O)(=O)C1=CN(C)C(=C1)C(=O)NC1=CC=C(F)C(=C1)C#N)C(F)(F)F

Targets

P03148C

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

11Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Bersacapavir, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account